📊 BIO-B Key Takeaways
Investment Thesis
Bio-Rad demonstrates exceptional profitability with a 29.4% net margin and strong balance sheet fundamentals, but growth stagnation (0% revenue YoY) and critically weak operating margin of 1.8% raise concerns about operational efficiency and sustainability. The dramatic 141% net income spike appears driven by non-operating items rather than core business improvement, warranting caution despite solid liquidity and cash generation.
BIO-B Strengths
- Exceptional net profit margin of 29.4% indicating strong bottom-line profitability despite operational challenges
- Fortress balance sheet with debt/equity of 0.16x, current ratio of 5.62x, and substantial free cash flow of $374.6M
- Strong free cash flow generation of $374.6M ($14.5% FCF margin) provides financial flexibility and reinvestment capacity
BIO-B Risks
- Flat year-over-year revenue growth of 0% signals stalled top-line expansion and potential market maturity or competitive pressures
- Dangerously low operating margin of 1.8% despite 51.9% gross margin suggests severe operational inefficiencies or cost structure problems
- Interest coverage ratio of 1.0x indicates minimal debt service cushion; net income surge appears anomalous (141% YoY) and likely unsustainable, suggesting one-time gains masking underlying weakness
Key Metrics to Watch
- Revenue growth trajectory and segment performance to determine if 0% growth is temporary or structural
- Operating margin expansion and cost structure optimization to validate core business profitability
- Source of net income spike to assess sustainability and distinguish between operating improvements vs. one-time gains
BIO-B Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.62x current ratio provides a solid financial cushion.
BIO-B Profitability Ratios
BIO-B vs Default Sector
How BIO-RAD LABORATORIES, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIO-B Balance Sheet & Liquidity
BIO-B 5-Year Financial Trend
5-Year Trend Summary: BIO-RAD LABORATORIES, INC.'s revenue has remained relatively flat over the 5-year period, with a 9% decline. The most recent EPS of $-21.82 indicates the company is currently unprofitable.
BIO-B Growth Metrics (YoY)
BIO-B Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $649.7M | $39.9M | $1.46 |
| Q2 2025 | $638.5M | $64.0M | $11.67 |
| Q1 2025 | $585.4M | $64.0M | $2.29 |
| Q3 2024 | $632.1M | $69.0M | $3.64 |
| Q2 2024 | $638.5M | $69.0M | $-37.09 |
| Q1 2024 | $610.8M | $69.0M | $2.32 |
| Q3 2023 | $632.1M | $69.0M | $3.64 |
| Q2 2023 | $681.1M | $69.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIO-B Capital Allocation
BIO-B SEC Filings
Access official SEC EDGAR filings for BIO-RAD LABORATORIES, INC. (CIK: 0000012208)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIO-B
What is the AI rating for BIO-B?
BIO-RAD LABORATORIES, INC. (BIO-B) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIO-B's key strengths?
Exceptional net profit margin of 29.4% indicating strong bottom-line profitability despite operational challenges. Fortress balance sheet with debt/equity of 0.16x, current ratio of 5.62x, and substantial free cash flow of $374.6M.
What are the risks of investing in BIO-B?
Flat year-over-year revenue growth of 0% signals stalled top-line expansion and potential market maturity or competitive pressures. Dangerously low operating margin of 1.8% despite 51.9% gross margin suggests severe operational inefficiencies or cost structure problems.
What is BIO-B's revenue and growth?
BIO-RAD LABORATORIES, INC. reported revenue of $2.6B.
Does BIO-B pay dividends?
BIO-RAD LABORATORIES, INC. does not currently pay dividends.
Where can I find BIO-B SEC filings?
Official SEC filings for BIO-RAD LABORATORIES, INC. (CIK: 0000012208) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIO-B's EPS?
BIO-RAD LABORATORIES, INC. has a diluted EPS of $27.85.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.